VIZIMPRO is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations [see Patient Selection under Dosage & Administration].
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign Out
